Eli Lilly and Company - Product News
Lilly's CYRAMZA™ (ramucirumab) Significantly Improves Overall Survival In Phase III Non-Small Cell Lung Cancer Study
Posted: June 2, 2014, 10:30 pm
Lilly Announces Increased Access to Clinical Trials Data for Qualified Researchers
Posted: June 2, 2014, 12:00 pm
Thousands to Create Mural Launching National Community Art Movement Honoring Those Touched by Cancer
Thousands to Create Mural Launching National Community Art Movement Honoring Those Touched by Cancer
Posted: May 29, 2014, 1:25 pm
Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
Posted: May 28, 2014, 11:00 am
Lilly Announces Date for Investor Web Call; Plans To Share Phase III Dulaglutide Data
Posted: May 27, 2014, 6:00 pm
Type 2 diabetes: European Commission approves Jardiance® (empagliflozin) tablets for use in adults in Europe
Posted: May 23, 2014, 10:00 am
Lilly Announces Date for Investor Webcast To Review Data Presented at ASCO 2014
Posted: May 16, 2014, 1:03 pm
Type 2 diabetes: findings presented from retrospective analysis of pooled data examining linagliptin in African-American adults
Posted: May 15, 2014, 4:45 pm
Lilly's Necitumumab Improves Overall Survival In Largest Ever Phase III Study In First-Line Treatment Of Stage IV Squamous Non-Small Cell Lung Cancer
Posted: May 14, 2014, 9:00 pm
Abemaciclib - Lilly's Oral CDK 4/6 Inhibitor - Shows Single-Agent Activity In A Phase I Study For Patients With A Specific Type Of Lung Cancer
Posted: May 14, 2014, 9:00 pm